David O'Malley, MD | Authors


Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer

August 23, 2018

David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.